Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib

Bayer76 enrolled

Overview

The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic colorectal cancer(mCRC) patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017. In addition, this study aims to describe the clinical characteristics of Belgian patients with a short- or long-term DoT to Stivarga.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Colorectal Neoplasms

Interventions

Regorafenib (Stivarga, BAY73-4506)DRUG

Antineoplastic agents, protein kinase inhibitor (L01XE21)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients ≥ 18 years of age. * Patients who suffer from mCRC and who started treatment with Stivarga between the 1st of July 2015 and 31 July 2017. * Patients who already received alternative treatment options before Stivarga for the treatment of mCRC or who were not eligible for other treatment options. * Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1 at start of Stivarga treatment. * Sufficient kidney, liver and bone marrow function start of Stivarga treatment. * Life expectancy ≥ 3 months at start of Stivarga treatment Exclusion Criteria: \- Patients participating in an investigational program/clinical trial with interventions outside of routine clinical practice during the observational period.

Locations (1)

Belgium

Multiple Locations, Belgium